Considering the ambivalent nature of copper as oncogenic and cytotoxic, upcoming RCC trials would be well-advised to look into combination approaches—combining copper modulators with VEGF inhibitors or immunotherapy checkpoint blockade—to leverage the context-dependent nature of copper. This evidence concerns the gene VEGFA and renal cell carcinoma.